AU2697197A - Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction - Google Patents

Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction

Info

Publication number
AU2697197A
AU2697197A AU26971/97A AU2697197A AU2697197A AU 2697197 A AU2697197 A AU 2697197A AU 26971/97 A AU26971/97 A AU 26971/97A AU 2697197 A AU2697197 A AU 2697197A AU 2697197 A AU2697197 A AU 2697197A
Authority
AU
Australia
Prior art keywords
osmolyte
betaine
cells
amino acids
taurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26971/97A
Other languages
English (en)
Inventor
Dieter Haussinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2697197A publication Critical patent/AU2697197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU26971/97A 1996-04-12 1997-04-14 Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction Abandoned AU2697197A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9601395 1996-04-12
SE9601395A SE9601395D0 (sv) 1996-04-12 1996-04-12 New therapeutic treatment 1
PCT/EP1997/001862 WO1997038686A1 (en) 1996-04-12 1997-04-14 Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction

Publications (1)

Publication Number Publication Date
AU2697197A true AU2697197A (en) 1997-11-07

Family

ID=20402174

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26971/97A Abandoned AU2697197A (en) 1996-04-12 1997-04-14 Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction

Country Status (7)

Country Link
EP (1) EP0910361A1 (no)
JP (1) JP2000508331A (no)
AU (1) AU2697197A (no)
CA (1) CA2251204A1 (no)
NO (1) NO984760L (no)
SE (1) SE9601395D0 (no)
WO (1) WO1997038686A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
AUPO821097A0 (en) * 1997-07-25 1997-08-14 Cultor Ltd. A prophylactic
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
EP2258183A1 (en) * 1998-12-22 2010-12-08 The University of North Carolina at Chapel Hill Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
US20030147937A1 (en) * 2000-04-12 2003-08-07 Thomas Schwarz Use of compatible solutes as substances having free radical scavenging properties
CA2386985A1 (en) * 2000-08-11 2002-02-21 The Lawson Health Research Institute Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
JP2008526789A (ja) * 2005-01-05 2008-07-24 アーメッド コトブ アブダラ，マグド タウリンの合成、生成及び医薬としての利用
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
JP2008537734A (ja) * 2005-03-12 2008-09-25 ビトップ アクツィエンゲゼルシャフト フュール ビオテヒニシェ オプティミールング 経口で用いられる適合溶質を含む薬剤
CA2650556A1 (en) 2005-04-27 2006-11-02 Jallal Messadek Insulins combinations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3728444A (en) * 1971-04-28 1973-04-17 Stanley Drug Products Inc Method and compositions for inducing resistance to bacterial infections
AU7584891A (en) * 1990-03-19 1991-10-21 Brigham And Women's Hospital Treatment of osmotic disturbance with organic osmolytes
AU641529B2 (en) * 1990-07-30 1993-09-23 Bloomfield D.A. Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions
TW282398B (no) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
US5516798A (en) * 1994-10-11 1996-05-14 North Carolina State University Method for treating diarrhea and a composition therefor

Also Published As

Publication number Publication date
WO1997038686A1 (en) 1997-10-23
CA2251204A1 (en) 1997-10-23
JP2000508331A (ja) 2000-07-04
NO984760D0 (no) 1998-10-12
EP0910361A1 (en) 1999-04-28
NO984760L (no) 1998-10-12
SE9601395D0 (sv) 1996-04-12

Similar Documents

Publication Publication Date Title
Du et al. Adaptations of hepatic lipid metabolism and mitochondria in dairy cows with mild fatty liver
Kim et al. Attenuation of bacterial lipopolysaccharide-induced hepatotoxicity by betaine or taurine in rats
Zhao et al. Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy
Li et al. Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia
US9623042B2 (en) Combination preparation for improving sperm quality
El‐Kirsh et al. The effect of L‐arginine or L‐citrulline supplementation on biochemical parameters and the vascular aortic wall in high‐fat and high‐cholesterol‐fed rats
AU2697197A (en) Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction
Hollinger et al. Case management and plasma half-life in a case of brodifacoum poisoning
Fiaccadori et al. Nutritional support in acute kidney injury
US5880098A (en) Therapeutic treatment
Naghii et al. Antioxidant therapy prevents ethylene glycol-induced renal calcium oxalate crystal deposition in Wistar rats
Pan et al. Arginine transport in catabolic disease states
Idrovo et al. Post-treatment with the combination of 5-aminoimidazole-4-carboxyamide ribonucleoside and carnitine improves renal function after ischemia/reperfusion injury
Li et al. Arginine metabolism regulates the pathogenesis of inflammatory bowel disease
Le Boucher et al. Enteral administration of ornithine alpha-ketoglutarate or arginine alpha-ketoglutarate: a comparative study of their effects on glutamine pools in burn-injured rats
Khalifa et al. Potential cardioprotective effect of octreotide via NOXs mitigation, mitochondrial biogenesis and MAPK/Erk1/2/STAT3/NF-kβ pathway attenuation in isoproterenol-induced myocardial infarction in rats
Maezono et al. Alanine protects liver from injury caused by D‐galactosamine and CCl4
Yang et al. The role of tea tree oil in alleviating palmitic acid-induced lipid accumulation in bovine hepatocytes
Porta et al. Effects of dietary protein on the liver of rats in experimental chronic alcoholism
Zhang et al. Dietary N-carbamylglutamate and L-arginine supplementation improves redox status and suppresses apoptosis in the colon of intrauterine growth-retarded suckling lambs
EP0946167A1 (en) Use of an osmolyte in the preparation of a medicament for treating complications resulting from ischemia
KR20220128629A (ko) 화학요법 부작용의 예방 및 치료에 사용하기 위한 아미노산을 포함하는 조성물(compositions comprising amino acids for use in the prevention and treatment of chemotherapy side effects)
KR0178799B1 (ko) 면역계 활성을 증가시키기 위한 약학 조성물
Sukhotnik et al. Effect of low fat diet on lipid absorption and fatty-acid transport following bowel resection
Vitale et al. Alcohol and vitamin metabolism

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted